UBS raised the firm’s price target on Adient (ADNT) to $15 from $13 and keeps a Neutral rating on the shares. Tariff mitigation led to a reiterated outlook for fiscal 2025, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADNT: